Rating Change
Wedbush reiterated its Outperform rating on Beam Therapeutics Inc. (NASDAQ:BEAM) on October 14, 2026.
reiterateNASDAQ:BEAM
Wedbush Reiterates Outperform Rating on Beam Therapeutics Inc. (BEAM)
Wedbush reiterated its Outperform rating on Beam Therapeutics Inc. (NASDAQ:BEAM) on October 14, 2026.
At publication ·
What changed
Beam Therapeutics Inc. (NASDAQ:BEAM) · reiterate
- Firm
- Wedbush
- Rating
- Outperform to Outperform
- Price at event
- $23.65
- Market capitalization
- $2.8B
At a glance
Key takeaways
- Wedbush maintained an Outperform rating on Beam Therapeutics (BEAM) on October 14, 2026, with the stock trading at $23.65 and a market cap of $2.8 billion.
Market Context
Beam Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $23.65 with a market capitalization of $2.8B. The stock has declined 6.8% over the past 52 weeks.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Beam Therapeutics Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Beam Therapeutics Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 14, 2026 | Wedbush | Outperform | N/A |
| Sep 09, 2026 | Wedbush | Outperform | N/A |
| Aug 25, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jul 08, 2026 | B of A Securities | Buy | N/A |
| Jul 07, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View BEAM Stock Page
Frequently Asked Questions
What does the Outperform rating mean for BEAM?
A rating of Outperform from Wedbush reflects the analyst's outlook on Beam Therapeutics Inc. (NASDAQ:BEAM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BEAM forecast page.
